Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.

World journal of gastroenterology - 7 Jun 2014

Sugimoto Mitsushige, Furuta Takahisa

Abstract excerpt

The cure rates of Helicobacter pylori (H. pylori) eradication therapy using a proton pump inhibitor (PPI) and antimicrobial agents such as amoxicillin, clarithromycin, and metronidazole are mainly influenced by bacterial susceptibility to antimicrobial agents and the magnitude of the inhibition of acid secretion. Annual cure rates have gradually decreased because of the increased prevalence of H. pylori strains...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to Clarithromycin
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Helicobacter Infections

Share to Helicobacter pylori

Share to Microbial Sensitivity Tests

Share to Proton Pump Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 24914361
DOI: 10.3748/wjg.v20.i21.6400
PMCID: PMC4047325

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.PMID 24914361Read ↗

Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori.Semantic proximity Read ↗

CYP2C19 polymorphism influences Helicobacter pylori eradication.Semantic proximity Read ↗

[Effectiveness of eradication regimen based on the bacterial susceptibility and CYP2C19 genotype in children with refractory Helicobacter pylori infection].Semantic proximity Read ↗

Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance.Semantic proximity Read ↗

CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.Semantic proximity Read ↗

Current and future insights in H. pylori eradication regimens: the need of tailoring therapy.Semantic proximity Read ↗

Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial.Semantic proximity Read ↗

Effect of bacterial and host factors onHelicobacter pylorieradication therapySemantic proximity Read ↗

Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection.Semantic proximity Read ↗

CYP2C19 Genotype, CagA Genotype and Antibiotic Resistant Strain of Helicobacter pylori InfectionSemantic proximity Read ↗

Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.